We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function.
Current Biology : CB 1997 April 2
BACKGROUND: The invertebrate and vertebrate Smad proteins have recently been identified as important mediators of the responses to transforming growth factor beta (TGF-beta) and related factors. We have previously shown that Smad3 and Smad4 (the product of the tumor suppressor gene DPC 4) strongly synergize as mediators of TGF-beta signaling, and that inactive carboxy-terminally truncated mutants of either Smad act as dominant-negative inhibitors of the natural TGF-beta response. The finding that Smad4, unlike Smad3, does not interact with the TGF-beta receptor, coupled with the distinct structural features of Smad4, raises the possibility that Smad4 cooperates not only with Smad3, but also with Smad1 and Smad2 to mediate signaling by TGF-beta family members.
RESULTS: Overexpression of Smad4 in 'animal caps' taken from Xenopus embryos induced both ventral and dorsal mesoderm, thereby mimicking the effects of TGF-beta family members - bone morphogenetic protein-2 (BMP-2) or BMP-4 and activin, respectively. Low levels of Smad4 mRNA coinjected with Smad1 or Smad2 mRNA also synergized to induce ventral or dorsal mesoderm, respectively. In addition, Smad4 synergized Smad2, as it does with Smad3, to induce gene expression from the promoter for plasminogen activator inhibitor-1. The carboxy-terminal domains of both Smad3 and Smad4 were required for this synergy. Finally, a short carboxy-terminal truncation of Smad4, previously identified as a mutation of DPC 4 in tumors, blocked nuclear translocation of wild-type Smads 1, 2, 3 and 4, consistent with our observation of a physical interaction between truncated Smad4 and the other Smads.
CONCLUSIONS: Our observations indicate that Smad4 cooperates with Smad1, Smad2 and Smad3 to act as a common mediator of signaling by TGF-beta-related factors, and provide a mechanism that explains the dominant-negative interference with receptor signaling that results from expression of the naturally occurring Smad4/DPC 4 truncation mutant.
RESULTS: Overexpression of Smad4 in 'animal caps' taken from Xenopus embryos induced both ventral and dorsal mesoderm, thereby mimicking the effects of TGF-beta family members - bone morphogenetic protein-2 (BMP-2) or BMP-4 and activin, respectively. Low levels of Smad4 mRNA coinjected with Smad1 or Smad2 mRNA also synergized to induce ventral or dorsal mesoderm, respectively. In addition, Smad4 synergized Smad2, as it does with Smad3, to induce gene expression from the promoter for plasminogen activator inhibitor-1. The carboxy-terminal domains of both Smad3 and Smad4 were required for this synergy. Finally, a short carboxy-terminal truncation of Smad4, previously identified as a mutation of DPC 4 in tumors, blocked nuclear translocation of wild-type Smads 1, 2, 3 and 4, consistent with our observation of a physical interaction between truncated Smad4 and the other Smads.
CONCLUSIONS: Our observations indicate that Smad4 cooperates with Smad1, Smad2 and Smad3 to act as a common mediator of signaling by TGF-beta-related factors, and provide a mechanism that explains the dominant-negative interference with receptor signaling that results from expression of the naturally occurring Smad4/DPC 4 truncation mutant.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app